David M. Brett‐Major, Kevin D. Frick, Jennifer A. Malia, Shilpa Hakre, Jason F. Okulicz, Charmagne G. Beckett, Linda L. Jagodinski, Michael A. Forgione, Philip L. Gould, Stephen A. Harrison, Clinton K. Murray, Francisco J. Rentas, Adam W. Armstrong, Aatif M. Hayat, Laura A. Pacha, Peter Dawson, Angelia A. Eick‐Cost, Hala H. Maktabi, Nelson L. Michael, Steven B. Cersovsky, Sheila A. Peel, Paul T. Scott – 20 October 2015 – Knowledge of the contemporary epidemiology of hepatitis C viral (HCV) infection among military personnel can inform potential Department of Defense screening policy.

Neil Rajoriya, Joanna A Leithead, Ahmed M Elsharkawy, Bridget K Gunson, Thamara M Perera, David Mutimer – 19 October 2015

Joshua Weiner, Adam Griesemer, Eddie Island, Steven Lobritto, Mercedes Martinez, Gennaro Selvaggi, Jay Lefkowitch, Monica Velasco, Panagiotis Tryphonopoulos, Jean Emond, Andreas Tzakis, Tomoaki Kato – 19 October 2015 – By preserving part of the native liver, auxiliary partial orthotopic liver transplantation (APOLT) provides the advantage of potential immunosuppression (ISP) withdrawal if the native liver recovers but has had limited acceptance, especially in the United States, due to technical complications and low rates of native liver regeneration.

Nikolaos Ouzounidis, Alexandros Giakoustidis, Theofilos Poutahidis, Katerina Angelopoulou, Stavros Iliadis, Antonis Chatzigiagkos, Argyro Zacharioudaki, Stamatis Angelopoulos, Apostolos Papalois, Vasilios Papanikolaou, Dimitrios Giakoustidis – 19 October 2015 – Inflammation‐associated oxidative stress contributes to hepatic ischemia/reperfusion injury (IRI). Detrimental inflammatory event cascades largely depend on activated Kupffer cells (KCs) and neutrophils, as well as proinflammatory cytokines, including tumor necrosis factor α (TNF‐α) and interleukin (IL) 18.

Neil Mehta, Monika Sarkar, Jennifer L. Dodge, Nicholas Fidelman, John P. Roberts, Francis Y. Yao – 19 October 2015 – Patients with T1 hepatocellular carcinoma (HCC; 1 lesion < 2 cm) are currently not eligible for priority listing for liver transplantation (LT). A common practice is to wait without locoregional therapy (LRT) until tumor growth occurs from T1 to T2 (1 lesion 2‐5 cm or 2‐3 lesions ≤ 3 cm) to be eligible for listing with Model for End‐Stage Liver Disease exception.

Meghan E. Sise, Allyson K. Bloom, Jessica Wisocky, Ming V. Lin, Jenna L. Gustafson, Andrew L. Lundquist, David Steele, Michael Thiim, Winfred W. Williams, Nikroo Hashemi, Arthur Y. Kim, Ravi Thadhani, Raymond T. Chung – 17 October 2015 – Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome (MCS). The efficacy and safety of all‐oral direct‐acting antiviral (DAA) therapy in HCV‐associated MCS (HCV‐MCS) is largely unknown.

Jean‐Louis Delaunay, Anne‐Marie Durand‐Schneider, Claire Dossier, Thomas Falguières, Julien Gautherot, Anne Davit‐Spraul, Tounsia Aït‐Slimane, Chantal Housset, Emmanuel Jacquemin, Michèle Maurice – 17 October 2015 – Progressive familial intrahepatic cholestasis type 3 is caused by biallelic variations of ABCB4, most often (≥70%) missense. In this study, we examined the effects of 12 missense variations identified in progressive familial intrahepatic cholestasis type 3 patients.

Kathie Beland, Fernando Alvarez – 17 October 2015

Jin‐Zhong Dong, Li‐Ping Wang, Jian‐Hua Zhu – 17 October 2015

Kiran M. Bambha – 17 October 2015